357 related articles for article (PubMed ID: 33391187)
1. Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy.
Smith TJ
Front Endocrinol (Lausanne); 2020; 11():610337. PubMed ID: 33391187
[TBL] [Abstract][Full Text] [Related]
2. Teprotumumab in Thyroid-Associated Ophthalmopathy: Rationale for Therapeutic Insulin-Like Growth Factor-I Receptor Inhibition.
Smith TJ
J Neuroophthalmol; 2020 Mar; 40(1):74-83. PubMed ID: 32040069
[TBL] [Abstract][Full Text] [Related]
3. IGF1 receptor and thyroid-associated ophthalmopathy.
Mohyi M; Smith TJ
J Mol Endocrinol; 2018 Jul; 61(1):T29-T43. PubMed ID: 29273685
[TBL] [Abstract][Full Text] [Related]
4. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives.
Mishra S; Maurya VK; Kumar S; Ankita ; Kaur A; Saxena SK
Curr Eye Res; 2020 Nov; 45(11):1325-1341. PubMed ID: 32567373
[TBL] [Abstract][Full Text] [Related]
5. Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy.
Slentz DH; Nelson CC; Smith TJ
Expert Opin Investig Drugs; 2020 Jul; 29(7):645-649. PubMed ID: 32429706
[TBL] [Abstract][Full Text] [Related]
6. Lessons Learned from Targeting IGF-I Receptor in Thyroid-Associated Ophthalmopathy.
Janssen JAMJL; Smith TJ
Cells; 2021 Feb; 10(2):. PubMed ID: 33673340
[TBL] [Abstract][Full Text] [Related]
7. Thyroid-associated ophthalmopathy: Emergence of teprotumumab as a promising medical therapy.
Smith TJ
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101383. PubMed ID: 32088116
[TBL] [Abstract][Full Text] [Related]
8. The insulin-like growth factor-I receptor and its role in thyroid-associated ophthalmopathy.
Smith TJ
Eye (Lond); 2019 Feb; 33(2):200-205. PubMed ID: 30385883
[TBL] [Abstract][Full Text] [Related]
9. Teprotumumab: The Dawn of Therapies in Moderate-to-Severe Thyroid-Associated Ophthalmopathy.
Ding Y; Yang S; Gao H
Horm Metab Res; 2021 Apr; 53(4):211-218. PubMed ID: 33853117
[TBL] [Abstract][Full Text] [Related]
10. Insulin-Like Growth Factor Pathway and the Thyroid.
Smith TJ
Front Endocrinol (Lausanne); 2021; 12():653627. PubMed ID: 34149612
[TBL] [Abstract][Full Text] [Related]
11. Teprotumumab Divergently Alters Fibrocyte Gene Expression: Implications for Thyroid-associated Ophthalmopathy.
Fernando R; Smith TJ
J Clin Endocrinol Metab; 2022 Sep; 107(10):e4037-e4047. PubMed ID: 35809263
[TBL] [Abstract][Full Text] [Related]
12. 2021 update on thyroid-associated ophthalmopathy.
Neag EJ; Smith TJ
J Endocrinol Invest; 2022 Feb; 45(2):235-259. PubMed ID: 34417736
[TBL] [Abstract][Full Text] [Related]
13. Teprotumumab (Tepezza): from the discovery and development of medicines to USFDA approval for active thyroid eye disease (TED) treatment.
Ali F; Chorsiya A; Anjum V; Ali A
Int Ophthalmol; 2021 Apr; 41(4):1549-1561. PubMed ID: 33481154
[TBL] [Abstract][Full Text] [Related]
14. Thyroid Eye Disease, Teprotumumab, and Hearing Loss: An Evolving Role for Otolaryngologists.
Chern A; Dagi Glass LR; Gudis DA
Otolaryngol Head Neck Surg; 2021 Dec; 165(6):757-758. PubMed ID: 33781112
[TBL] [Abstract][Full Text] [Related]
15. Teprotumumab: First Approval.
Markham A
Drugs; 2020 Apr; 80(5):509-512. PubMed ID: 32157641
[TBL] [Abstract][Full Text] [Related]
16. Treating Thyroid Associated Ophthalmopathy in Pediatric Patients.
Dong T; Fu Z; Wang X
Front Endocrinol (Lausanne); 2022; 13():900204. PubMed ID: 35837312
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy.
Fernando R; Caldera O; Smith TJ
Proc Natl Acad Sci U S A; 2021 Dec; 118(52):. PubMed ID: 34949642
[TBL] [Abstract][Full Text] [Related]
18. Teprotumumab for Thyroid-Associated Ophthalmopathy.
Smith TJ; Kahaly GJ; Ezra DG; Fleming JC; Dailey RA; Tang RA; Harris GJ; Antonelli A; Salvi M; Goldberg RA; Gigantelli JW; Couch SM; Shriver EM; Hayek BR; Hink EM; Woodward RM; Gabriel K; Magni G; Douglas RS
N Engl J Med; 2017 May; 376(18):1748-1761. PubMed ID: 28467880
[TBL] [Abstract][Full Text] [Related]
19. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
[TBL] [Abstract][Full Text] [Related]
20. Teprotumumab for the treatment of thyroid eye disease.
Ju Y; Yang J
Expert Rev Clin Immunol; 2020 Aug; 16(8):739-743. PubMed ID: 32707005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
